Promising Aids trials provide a shot in the arm for Glaxo

Promising Aids trial results over the weekend gave a fillip to Glaxo Wellcome's portfolio of new and existing HIV drugs. The company said it was "encouraged by these initial reports" even if it was too early to draw firm conclusions from a relatively small trial.

According to Glaxo, a majority of patients suffering from human immunodeficiency virus, the precursor to full-blown Aids, saw levels of the virus drop to undetectable levels following four weeks of treatment with two new compounds under development by the drugs giant. There was also no sign of any resistance to the combined treatment, a problem which has dogged some other anti-Aids drugs.

The news, released at a Washington medical conference yesterday, came alongside encouraging results from trials involving a "triple cocktail" of drugs using Glaxo's existing Retrovir (AZT) and Epivir (3TC) anti-Aids products in association with drugs developed by Abbott Laboratories and Merck, two US rivals to Glaxo.

Those tests offered hope for children who had inherited the HIV virus from their parents, seeming to suggest a cocktail of the drugs administered early could stop HIV in its tracks. Again, researchers stressed that it was too early to know for certain whether the drugs were completely effective.

Separately, DuPont Merck, a joint venture between the Delaware-based chemicals company and Merck, said an experimental drug known as DMP-266 in conjunction with another Merck treatment, Crixivan, had shown a fall in HIV blood counts below detectable levels in 82 per cent of patients.

The results of the new Glaxo drug trials, which were carried out by the University of Colorado Health Sciences Center, were greeted with cautious optimism by the company. Richard Kent, director of world-wide clinical research, said: "While it would be extremely premature to draw any conclusions based on such early results in such a small number of patients, we are encouraged by these initial reports."

Larger trials involving a variety of types of patient and different drug combinations were continuing, he added, "and we are working as quickly as possible to learn what their optimal role in therapy will be".

The new compounds involved are part of a new generation of anti-Aids drugs following on from Retrovir and Epivir. One, a so-called reverse transcriptase inhibitor codenamed 1592U89, was developed by Wellcome before its takeover by Glaxo as a successor to Epivir. The other is a protease inhibitor coded 141W94, which was invented by a US biotechnology company, Vertex Pharmaceuticals, and has been licensed to Glaxo.

The latest findings on the drugs' effectiveness in combination were released at the Fourth National Conference on Retroviruses and Opportunistic Infections in Washington. Five out of seven patients in the trial showed positive results, with the amount of virus in their bloodstream dropping to below 400 detections per millilitre, while infection-fighting CD4 cells increased over the four-week period. The drugs were said to be "well tolerated", although nausea is clearly a problem, forcing one patient to discontinue the treatment.

Even so, analysts are expected to generally welcome the results as confirming the value of combination therapy in the battle against Aids. Anthony Colletta of Glaxo's own brokers, Hoare Govett, said on Friday: "There are no fears about Glaxo's position in the HIV market... even on the most bearish forecast it will still have 50 per cent of the market by the year 2000."

By then he expects the group's anti-Aids portfolio to be generating sales of pounds 1.15bn, out of the total of pounds 5.6bn forecast to be coming from new drugs launched between 1993 and 2000. Within that, the 1592 compound will be turning over pounds 112m, while 141W sales could be pounds 121m, he believes. The trials on children, conducted by the University of Massachusetts, are similar to a study by leading Aids researcher David Ho. In his study of newly-infected HIV adults, he found that a mixture of Abbott Laboratories' Norvir with Glaxo Wellcome's AZT and 3TC could reduce the level of HIV in patients' blood to below detectable levels.

It also appeared to stop the disease's reproduction in the lymphoid tissue and elsewhere in the body.

He found similar effects with a mix of Merck's Crixivan and 3TC and AZT.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
News
ebooksNow available in paperback
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Sheridan Maine: Commercial Finance Manager

Up to £70,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...

Sheridan Maine: Regulatory Reporting Accountant

Up to £65,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...

Ashdown Group: Marketing Services Manager - (communications, testing, DM)

£32000 - £35000 per annum + benefits: Ashdown Group: Marketing Services Manage...

Guru Careers: Finance Account Manager

£Neg. (DOE) + Excellent Benefits: Guru Careers: A Finance Account Manager with...

Day In a Page

Homeless Veterans appeal: 'You look for someone who's an inspiration and try to be like them'

Homeless Veterans appeal

In 2010, Sgt Gary Jamieson stepped on an IED in Afghanistan and lost his legs and an arm. He reveals what, and who, helped him to make a remarkable recovery
Could cannabis oil reverse the effects of cancer?

Could cannabis oil reverse effects of cancer?

As a film following six patients receiving the controversial treatment is released, Kate Hilpern uncovers a very slippery issue
The Interview movie review: You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here

The Interview movie review

You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here
Serial mania has propelled podcasts into the cultural mainstream

How podcasts became mainstream

People have consumed gripping armchair investigation Serial with a relish typically reserved for box-set binges
Jesus Christ has become an unlikely pin-up for hipster marketing companies

Jesus Christ has become an unlikely pin-up

Kevin Lee Light, aka "Jesus", is the newest client of creative agency Mother while rival agency Anomaly has launched Sexy Jesus, depicting the Messiah in a series of Athena-style poses
Rosetta space mission voted most important scientific breakthrough of 2014

A memorable year for science – if not for mice

The most important scientific breakthroughs of 2014
Christmas cocktails to make you merry: From eggnog to Brown Betty and Rum Bumpo

Christmas cocktails to make you merry

Mulled wine is an essential seasonal treat. But now drinkers are rediscovering other traditional festive tipples. Angela Clutton raises a glass to Christmas cocktails
5 best activity trackers

Fitness technology: 5 best activity trackers

Up the ante in your regimen and change the habits of a lifetime with this wearable tech
Paul Scholes column: It's a little-known fact, but I have played one of the seven dwarves

Paul Scholes column

It's a little-known fact, but I have played one of the seven dwarves
Fifa's travelling circus once again steals limelight from real stars

Fifa's travelling circus once again steals limelight from real stars

Club World Cup kicked into the long grass by the continued farce surrounding Blatter, Garcia, Russia and Qatar
Frank Warren column: 2014 – boxing is back and winning new fans

Frank Warren: Boxing is back and winning new fans

2014 proves it's now one of sport's biggest hitters again
Jeb Bush vs Hillary Clinton: The power dynamics of the two first families

Jeb Bush vs Hillary Clinton

Karen Tumulty explores the power dynamics of the two first families
Stockholm is rivalling Silicon Valley with a hotbed of technology start-ups

Stockholm is rivalling Silicon Valley

The Swedish capital is home to two of the most popular video games in the world, as well as thousands of technology start-ups worth hundreds of millions of pounds – and it's all happened since 2009
Did Japanese workers really get their symbols mixed up and display Santa on a crucifix?

Crucified Santa: Urban myth refuses to die

The story goes that Japanese store workers created a life-size effigy of a smiling "Father Kurisumasu" attached to a facsimile of Our Lord's final instrument of torture
Jennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress

The Boy in the Dress: On set with the stars

Walliams' story about a boy who goes to school in a dress will be shown this Christmas